{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:57:43Z","timestamp":1780477063405,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,5,18]]},"DOI":"10.1038\/s41416-025-02971-0","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T17:48:51Z","timestamp":1742060931000},"page":"814-821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer"],"prefix":"10.1038","volume":"132","author":[{"given":"Adrien","family":"Grancher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludivine","family":"Beaussire-Trouvay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Dutherage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Blondin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Elie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Bouhier-Leporrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Galais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tifenn","family":"Clabaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Bignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Parzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Gangloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"L\u00e9v\u00eaque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Sabourin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Vasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0821-5642","authenticated-orcid":false,"given":"David","family":"Sefrioui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Gilibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5237-2971","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Di Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"2971_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2971_CR2","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:1386\u2013422.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2971_CR3","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065\u201375.","journal-title":"Lancet Oncol"},{"key":"2971_CR4","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer. JAMA. 2017;317:2392\u2013401.","journal-title":"JAMA"},{"key":"2971_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"C Cremolini","year":"2020","unstructured":"Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21:497\u2013507.","journal-title":"Lancet Oncol"},{"key":"2971_CR6","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"A Falcone","year":"2007","unstructured":"Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:1670\u20136.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2971_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamaoncol.2017.5314","volume":"4","author":"C Cremolini","year":"2018","unstructured":"Cremolini C, Antoniotti C, Lonardi S, Aprile G, Bergamo F, Masi G, et al. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. JAMA Oncol. 2018;4:529\u201336.","journal-title":"JAMA Oncol"},{"key":"2971_CR8","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609\u201318.","journal-title":"N Engl J Med"},{"key":"2971_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","volume":"10","author":"E Crowley","year":"2013","unstructured":"Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10:472\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"2971_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ccell.2017.01.002","volume":"31","author":"A Bardelli","year":"2017","unstructured":"Bardelli A, Pantel K. Liquid Biopsies, What We Do Not Know (Yet). Cancer Cell. 2017;31:172\u20139.","journal-title":"Cancer Cell"},{"key":"2971_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cca.2013.05.022","volume":"424","author":"S El Messaoudi","year":"2013","unstructured":"El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: Preanalytical considerations. Clin Chim Acta Int J Clin Chem. 2013;424:222\u201330.","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"2971_CR12","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1373\/49.6.1028","volume":"49","author":"M Jung","year":"2003","unstructured":"Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K. Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem. 2003;49:1028\u20139.","journal-title":"Clin Chem"},{"key":"2971_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","volume":"32","author":"LA Diaz","year":"2014","unstructured":"Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:579\u201386.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2971_CR14","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985\u201390.","journal-title":"Nat Med"},{"key":"2971_CR15","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1158\/1078-0432.CCR-11-0564","volume":"18","author":"KLG Spindler","year":"2012","unstructured":"Spindler KLG, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:1177\u201385.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2971_CR16","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1158\/1078-0432.CCR-15-0297","volume":"22","author":"S El Messaoudi","year":"2016","unstructured":"El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, et al. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:3067\u201377.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2971_CR17","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1158\/1078-0432.CCR-19-3467","volume":"26","author":"AR Parikh","year":"2020","unstructured":"Parikh AR, Mojtahed A, Schneider JL, Kanter K, Van Seventer EE, Fetter IJ, et al. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26:1877\u201385.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2971_CR18","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S1470-2045(15)00138-2","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;16:937\u201348.","journal-title":"Lancet Oncol"},{"key":"2971_CR19","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/annonc\/mdv177","volume":"26","author":"J Tie","year":"2015","unstructured":"Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2015;26:1715\u201322.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2971_CR20","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1158\/1078-0432.CCR-16-3155","volume":"23","author":"F Garlan","year":"2017","unstructured":"Garlan F, Laurent-Puig P, Sefrioui D, Siauve N, Didelot A, Sarafan-Vasseur N, et al. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:5416\u201325.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2971_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-021-01431-9","volume":"125","author":"D Sefrioui","year":"2021","unstructured":"Sefrioui D, Beaussire L, Gillibert A, Blanchard F, Toure E, Bazille C, et al. CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC). Br J Cancer. 2021;125:725\u201333.","journal-title":"Br J Cancer"},{"key":"2971_CR22","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41416-022-01837-z","volume":"127","author":"S Kim","year":"2022","unstructured":"Kim S, Lim Y, Kang JK, Kim HP, Roh H, Kim SY, et al. Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment. Br J Cancer. 2022;127:898\u2013907.","journal-title":"Br J Cancer"},{"key":"2971_CR23","first-page":"994","volume":"8","author":"MC Prewett","year":"2002","unstructured":"Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res Off J Am Assoc Cancer Res. 2002;8:994\u20131003.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2971_CR24","first-page":"227","volume":"1","author":"E Raymond","year":"2002","unstructured":"Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002;1:227\u201335.","journal-title":"Mol Cancer Ther"},{"key":"2971_CR25","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.1158\/1078-0432.CCR-07-1768","volume":"13","author":"M Prewett","year":"2007","unstructured":"Prewett M, Deevi DS, Bassi R, Fan F, Ellis LM, Hicklin DJ, et al. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13:7432\u201340.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2971_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16:409\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"2971_CR27","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci Transl Med. 2014;6:224ra24.","journal-title":"Sci Transl Med."},{"key":"2971_CR28","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/annonc\/mdy061","volume":"29","author":"JB Bachet","year":"2018","unstructured":"Bachet JB, Bouch\u00e9 O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:1211\u20139.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2971_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","volume":"17","author":"A Dasari","year":"2020","unstructured":"Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020;17:757\u201370.","journal-title":"Nat Rev Clin Oncol"},{"key":"2971_CR30","doi-asserted-by":"publisher","first-page":"9392","DOI":"10.1002\/cam4.5699","volume":"12","author":"G Martini","year":"2023","unstructured":"Martini G, Ciardiello D, Famiglietti V, Rossini D, Antoniotti C, Troiani T, et al. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS\/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials. Cancer Med. 2023;12:9392\u2013400.","journal-title":"Cancer Med"},{"key":"2971_CR31","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022;28:1612\u20138.","journal-title":"Nat Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02971-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02971-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02971-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:04:45Z","timestamp":1745917485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02971-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,5,18]]}},"alternative-id":["2971"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-02971-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work combine data from two trials, registered on the clinicaltrials.gov website (No. NCT01212510 and NCT02872779), and approved by an ethic committee (Comit\u00e9 de Protection des Personnes Nord-Ouest 1, Rouen University, 76000 France). Each patient included in these two trials gave written consent. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}